Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Blast Crisis 1

Interventions

Cyclophosphamide 53fludarabine phosphate 52Peripheral Blood Stem Cell Transplantation 52Busulfan 39Tacrolimus 36Mycophenolic Acid 32Methotrexate 31Cyclosporine 31Antilymphocyte Serum 31Filgrastim 26Whole-Body Irradiation 25Cytarabine 24Radiotherapy 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Melphalan 17Imatinib Mesylate 17Etoposide 16Flow Cytometry 12Thiotepa 11fludarabine 10Dasatinib 10Therapeutics 9Sirolimus 9Granulocyte Colony-Stimulating Factor 9nilotinib 8sargramostim 7Psychiatric Rehabilitation 7Decitabine 7Prednisone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blast Crisis × irofulven × Myeloid × Clear all
NCT00003997 2013-02-08

6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡